Search

Displaying results 2451 - 2460 of 7018 in total
  1. Drug

    Acetophenazine

    go.drugbank.com/drugs/DB01063
    Approved

    Acetophenazine is an antipsychotic drug of moderate-potency. It is used in the treatment of disorganized and psychotic thinking. … It is also used to help treat false perceptions (e.g. hallucinations or delusions). It primarily targets the dopamine D2 receptor.

  2. Drug

    Albutrepenonacog alfa

    go.drugbank.com/drugs/DB13884
    Approved

    Albutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX (rFIX) with a recombinant human albumin (rAlbumin). … [A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.

  3. Drug

    Quazepam

    go.drugbank.com/drugs/DB01589
    ApprovedIllicit

    Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. … [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other

  4. Drug

    Iodide I-131

    go.drugbank.com/drugs/DB09293
    ApprovedInvestigational

    Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. … As a result of beta decay, approximately 10% of its energy and radiation dose is via gamma radiation, while the other 90% (beta radiation) causes tissue damage without contributing to any ability to see

    Products: Natriumjodid (131I) Curium - Kapsel T
  5. Drug

    αAβ–Gas6

    go.drugbank.com/drugs/DB17069
    Experimental

    αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). … of AD.

  6. Drug

    Ridogrel

    go.drugbank.com/drugs/DB01207
    Experimental

    Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction.

    Categories: Thromboxane-A Synthase, antagonists & inhibitors
  7. Drug

    Zucapsaicin

    go.drugbank.com/drugs/DB09120
    ApprovedWithdrawn

    It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1, that reduces pain and improves articular functions. … Zucapsaicin, the cis-isomer of capsaicin, is a topical analgesic used to treat osteoarthritis of the knee and other neuropathic pain.

  8. Drug

    Quinupramine

    go.drugbank.com/drugs/DB13246
    Approved

    Quinupramine has been approved in France under the brand name Kinupril, as an antidepressant [A175003].

  9. Drug

    Domiphen

    go.drugbank.com/drugs/DB11594
    Approved

    Domiphen bromide is a quaternary ammonium compound that is predominantly employed as a topically administered antiseptic agent.

  10. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. … [A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease.[L8237] This drug was first approved in Japan on 25 March 2013.

    Categories: Adenosine A2 Receptor Antagonists